Clinical And Pathological Features Associated With Epidermal Growth Factor Receptor Gene Mutation In677Non-small Cell Lung Cancer Patients

BackgroundLung cancer is the leading cause of cancer death worldwide. Molecular targeting drugs has been the first-line treatment in these years. For many patients diagnosed as advanced lung cancer, surgical sample is unable to acquire. The clinical and patholo-gical characteristics are important to predict the gene mutation.ObjectiveTo investigate the clinical and pathological features associated with epidermal growth factor receptor gene mutation in non-small cell lung cancer.MethodsIn this series,677NSCLC patients from single center (during a period of2010.6through2013.7, The first affiliated hospital, School of medicine, Zhejiang University) were included in retrospective analysis, all of whom test the EGFR gene type through pyrosequencing. Daum were analyzed with SPSS19.0software. P values less than0.05were considered significant. ResultsAmong the677NSCLC patients, EGFR mutation rate was46.23%. It happened more frequently in female, non-smoke, good differentiated, stage I a-IIIa, adenocarcinoma patients (P<0.05). However, the mutation rate was lower in patients with AB blood type (P<0.05). Patients with mutated EGFR had a higher level of CEA than patients with wild tye (P=0.038). After logistic analysis, pathology, differentiation and blood type are independent factors that affecting the EGFR mutation.ConclusionIn the local area, NSCLC patients of female, non-smoker, good differentiated, stage â… a-â…¢a, adenocarcinoma patients have significantly higher incidence of EGFR mutation. Pathology, differentiation status and blood type have a significant impact on EGFR mutation.